Dr. Gerth says anecdotal results can sound promising but argues FDA approval and long-term safety data should guide decisions on newer treatments.
Recap by typeshit. Post by @drgerthplasticsurgery on Instagram.
Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
Researchers at the American Academy of Ophthalmology meeting found NAION patients on GLP-1 drugs tended to develop it in the other eye sooner.
32:25
The channel walks through FDA inspection findings of mold at suppliers and what people taking GLP-1 medications should watch for.
Two factories making semaglutide and tirzepatide for US compounders are now on the FDA import alert list. At one, staff were seen hiding papers and pouring samples down sinks.
Loading…